SID & Chair of Remuneration Committee
February 16, 2023
Senior Independent Director & Chair of Remuneration Committee
Indivior PLC (the "Company") today announces that Juliet Thompson has been appointed as Senior Independent Director with effect from October 1, 2023. Juliet has been a Non-Executive Director since March 2021 and is the Chair of the Audit Committee and a member of the Nomination & Governance Committee.
The Company further announces that Jo Le Couilliard has been appointed as Chair of the Remuneration Committee also with effect from October 1, 2023. Jo has been a Non-Executive Director since March 2021 and is a member of the Audit and Remuneration Committees.
This announcement follows the Company's previous announcement on October 13, 2022 that Daniel J. Phelan, current Senior Independent Director and Chair of the Remuneration Committee, will stand down from the Board on September 30, 2022 having served as a Director for nine years.
This announcement is made pursuant to Listing Rule 9.6.11.
About Indivior
Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD) and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 900 individuals globally and its portfolio of products is available in 39 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.
For Further Information
|
Jason Thompson |
VP, Investor Relations Indivior PLC |
+1 804 402 7123 jason.thompson@indivior.com |
|
Tim Owens |
Director, Investor Relations Indivior PLC |
+1 804 263 3978 timothy.owens@indivior.com |
-ends-
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 7 hours ago Luceco
- 7 hours ago Helios Towers
- 7 hours ago Wise Class A
- 7 hours ago EDX Medical Group Plc
- 8 hours ago Naked Wines